TELA Bio Pulls 2026 Outlook as Sales Fall, Loss Widens
MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) withdrew its full-year 2026 revenue guidance after second-quarter sales fell 4% and its net loss widened, with newly appointed Chief Executive Officer …
TELA Bio Pulls 2026 Outlook as Sales Fall, Loss Widens Read More